IN2014CN00414A - - Google Patents

Info

Publication number
IN2014CN00414A
IN2014CN00414A IN414CHN2014A IN2014CN00414A IN 2014CN00414 A IN2014CN00414 A IN 2014CN00414A IN 414CHN2014 A IN414CHN2014 A IN 414CHN2014A IN 2014CN00414 A IN2014CN00414 A IN 2014CN00414A
Authority
IN
India
Prior art keywords
amino acid
acid sequences
polypeptides
proteins
compositions
Prior art date
Application number
Inventor
Bruno Dombrecht
Peter Schotte
Cedric Jozef Néotére VERVERKEN
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of IN2014CN00414A publication Critical patent/IN2014CN00414A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Abstract

The present invention relates to amino acid sequences that are capable of binding to serum albumin; to proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences proteins or polypeptides; to compositions and in particular pharmaceutical compositions that comprise such amino acid sequences proteins and polypeptides; and to uses of such amino acid sequences proteins and polypeptides.
IN414CHN2014 2011-06-23 2012-06-14 IN2014CN00414A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161500464P 2011-06-23 2011-06-23
PCT/EP2012/061304 WO2012175400A1 (en) 2011-06-23 2012-06-14 Serum albumin binding proteins

Publications (1)

Publication Number Publication Date
IN2014CN00414A true IN2014CN00414A (en) 2015-04-03

Family

ID=46298413

Family Applications (1)

Application Number Title Priority Date Filing Date
IN414CHN2014 IN2014CN00414A (en) 2011-06-23 2012-06-14

Country Status (17)

Country Link
US (2) US9573992B2 (en)
EP (3) EP2723771B1 (en)
JP (3) JP6324887B2 (en)
CN (2) CN103619878B (en)
AU (1) AU2012271974B2 (en)
CA (1) CA2839779C (en)
CY (1) CY1122691T1 (en)
DK (1) DK2723771T3 (en)
ES (1) ES2759936T3 (en)
HR (2) HRP20170535T4 (en)
HU (1) HUE047238T2 (en)
IN (1) IN2014CN00414A (en)
LT (1) LT2723771T (en)
PL (1) PL2723771T3 (en)
PT (1) PT2723771T (en)
SI (1) SI2723771T1 (en)
WO (1) WO2012175400A1 (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012042026A1 (en) 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
CA3142288A1 (en) * 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2723771B1 (en) * 2011-06-23 2019-09-11 Ablynx NV Serum albumin binding proteins
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
CN106046161B (en) * 2011-09-30 2019-09-13 埃博灵克斯股份有限公司 Biological substance relevant to C-Met
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
IL295534A (en) 2014-05-16 2022-10-01 Ablynx Nv Improved immunoglobulin variable domains
US11009511B2 (en) 2014-05-16 2021-05-18 Ablynx N.V. Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
HUE050007T2 (en) 2014-05-16 2020-11-30 Ablynx Nv Immunoglobulin variable domains
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
CA2971278C (en) 2014-12-19 2023-09-19 Ablynx N.V. Cysteine linked nanobody dimers
CA2975059C (en) 2015-01-29 2023-02-21 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
ES2889906T3 (en) 2015-05-21 2022-01-14 Harpoon Therapeutics Inc Trispecific binding proteins and medical uses
NO2768984T3 (en) 2015-11-12 2018-06-09
HRP20220080T1 (en) 2015-11-13 2022-04-15 Ablynx N.V. Improved serum albumin-binding immunoglobulin variable domains
EP3377525A2 (en) * 2015-11-18 2018-09-26 Ablynx NV Improved serum albumin binders
EP3377526A1 (en) 2015-11-18 2018-09-26 Merck Sharp & Dohme Corp. PD1/CTLA4 Binders
TW202216787A (en) 2015-11-18 2022-05-01 美商默沙東藥廠 Pd1 and/or lag3 binders
EP3377527A1 (en) 2015-11-18 2018-09-26 Merck Sharp & Dohme Corp. Ctla4 binders
CA3006398A1 (en) 2015-11-27 2017-06-01 Ablynx Nv Polypeptides inhibiting cd40l
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EA201892691A1 (en) * 2016-05-20 2019-04-30 Харпун Терапьютикс, Инк. SINGLE-DOMAIN PROTEIN, BINDING SERUM ALBUMIN
EP4119944A1 (en) 2016-06-23 2023-01-18 Ablynx N.V. Improved pharmacokinetic assays for immunoglobulin single variable domains
CN110177809B (en) 2016-11-16 2023-11-03 埃博灵克斯股份有限公司 T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
AU2017373746A1 (en) * 2016-12-07 2019-05-30 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
CN107674122A (en) * 2016-12-28 2018-02-09 天津天锐生物科技有限公司 A kind of single domain antibody for identifying human serum albumins
AU2018209151A1 (en) * 2017-01-17 2019-07-25 Ablynx Nv Improved serum albumin binders
KR20230165374A (en) * 2017-01-17 2023-12-05 아블린쓰 엔.브이. Improved serum albumin binders
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
CN110546506B (en) 2017-03-31 2023-04-04 埃博灵克斯股份有限公司 Improved immunogenicity assays
CN110891974B (en) 2017-05-12 2021-08-06 哈普恩治疗公司 Mesothelin binding proteins
JP7066837B2 (en) 2017-10-13 2022-05-13 ハープーン セラピューティクス，インク． B cell maturation antigen binding protein
CN111630070A (en) 2017-10-13 2020-09-04 哈普恩治疗公司 Trispecific proteins and methods of use
TW202000238A (en) * 2018-02-26 2020-01-01 比利時商艾伯林克斯公司 Improved nucleotide sequences encoding peptide linkers
AU2019346466A1 (en) 2018-09-25 2021-05-20 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
CN110964107B (en) * 2018-09-30 2022-08-09 苏州康宁杰瑞生物科技有限公司 MET binding molecules, combinations and uses thereof
CN111138537B (en) * 2018-11-06 2021-07-09 瑞阳(苏州)生物科技有限公司 Anti-human serum albumin antibody fragment, preparation method and application
CN111138536B (en) * 2018-11-06 2021-07-09 瑞阳(苏州)生物科技有限公司 Preparation and application of anti-human serum albumin single-domain antibody
EP3969474A1 (en) * 2019-05-15 2022-03-23 Crescendo Biologics Limited Binding molecules
KR20220122652A (en) 2019-12-06 2022-09-02 아블린쓰 엔.브이. Polypeptides comprising immunoglobulin single variable domains targeting TNFα and IL-23
WO2021110817A1 (en) 2019-12-06 2021-06-10 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
US20210188965A1 (en) 2019-12-09 2021-06-24 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp
CN110988361B (en) * 2019-12-13 2020-09-18 山东民康生物科技有限公司 Human serum albumin removing kit
IL295448A (en) 2020-02-21 2022-10-01 Harpoon Therapeutics Inc Flt3 binding proteins and methods of use
WO2021198260A1 (en) 2020-03-30 2021-10-07 Ablynx Nv Method for the production and purification of multivalent immunoglobulin single variable domains
CA3195687A1 (en) 2020-09-25 2022-03-31 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
CN112142846B (en) * 2020-10-10 2022-07-08 西北大学 AOX specific antibody combination and preparation method and application thereof
CN115244076B (en) 2020-10-27 2023-08-04 北京质肽生物医药科技有限公司 GDF15 fusion proteins and uses thereof
CA3203141A1 (en) 2020-12-18 2022-06-23 Ablynx Nv T cell recruiting polypeptides based on tcr alpha/beta reactivity
TW202239763A (en) 2020-12-18 2022-10-16 比利時商艾伯霖克斯公司 Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-α
IL303783A (en) 2020-12-18 2023-08-01 Sanofi Sa Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
CN116635402B (en) * 2021-07-14 2024-03-15 北京质肽生物医药科技有限公司 Fusion polypeptides for metabolic disorders
TW202340240A (en) * 2021-11-17 2023-10-16 大陸商江蘇先聲藥業有限公司 Multi-specific antibody and its pharmaceutical uses
WO2023111266A1 (en) 2021-12-17 2023-06-22 Ablynx Nv POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123
WO2023134742A1 (en) * 2022-01-14 2023-07-20 浙江道尔生物科技有限公司 Three-target anti-tumor drug, and preparation method therefor and use thereof
WO2023242247A1 (en) 2022-06-14 2023-12-21 Ablynx Nv Immunoglobulin single variable domains targeting t cell receptor
WO2023242361A1 (en) 2022-06-15 2023-12-21 argenx BV Fcrn binding molecules and methods of use
WO2024023271A1 (en) 2022-07-27 2024-02-01 Ablynx Nv Polypeptides binding to a specific epitope of the neonatal fc receptor

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608039A (en) 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
ATE427968T1 (en) 1992-08-21 2009-04-15 Univ Bruxelles IMMUNOGLOBULINS WITHOUT LIGHT CHAIN
EP0698097B1 (en) 1993-04-29 2001-08-16 Unilever N.V. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6670453B2 (en) 1997-10-27 2003-12-30 Unilever Patent Holdings B.V. Multivalent antigen-binding proteins
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
FR2846667B1 (en) 2002-11-06 2004-12-31 Pasteur Institut VARIABLE FRAGMENTS OF SINGLE-CHAIN CAMELIDE ANTIBODIES DIRECTED AGAINST BETA-AMYLOID PEPTIDE 1-42 AND THEIR APPLICATIONS FOR DIAGNOSIS AND TREATMENT OF NEUROAGREGATIVE DISEASES
JP2006520584A (en) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． Stabilized single domain antibody
MXPA05006043A (en) 2003-01-10 2006-01-30 Ablynx Nv Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation.
RS51326B (en) * 2004-08-05 2010-12-31 Genentech Inc. Humanized anti-cmet antagonists
PL1888641T3 (en) 2005-05-18 2012-05-31 Ablynx Nv Serum albumin binding proteins
US7875465B2 (en) 2005-05-31 2011-01-25 Canon Kabushiki Kaisha Target substance capturing molecule
WO2006129843A2 (en) 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Bispecific capturing molecule
WO2007085814A1 (en) 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
CA2646048A1 (en) * 2006-03-30 2007-11-08 Novartis Ag Compositions and methods of use for antibodies of c-met
US7741273B2 (en) 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
ES2746925T3 (en) 2006-08-03 2020-03-09 Medimmune Ltd Antibodies Directed Towards alfaVbeta6 and Use of Them
JP2010500876A (en) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Amino acid sequence directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6 mediated signaling
JP2010502208A (en) 2006-09-08 2010-01-28 アブリンクス エン．ヴェー． Serum albumin binding protein with long half-life
CA2666511A1 (en) * 2006-10-11 2008-04-17 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and uses thereof
GB0706793D0 (en) 2007-04-05 2007-05-16 Evotec Ag Compounds
NZ581097A (en) 2007-05-24 2012-03-30 Ablynx Nv Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
CA2698343C (en) 2007-09-04 2018-06-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
US7867497B2 (en) 2007-09-24 2011-01-11 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses therefor
EP2215123A1 (en) 2007-11-27 2010-08-11 Ablynx N.V. Immunoglobulin constructs
WO2009097128A1 (en) 2008-01-29 2009-08-06 Ludwig Institute For Cancer Research Ltd. Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy
BRPI0911984A2 (en) 2008-05-16 2016-09-20 Ablynx Nv amino acid sequences directed against cxcr4 and other gpcrs compounds comprising the same
DK2285408T3 (en) 2008-06-05 2019-02-04 Ablynx Nv AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES
EP2143735A1 (en) 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
WO2010042815A2 (en) 2008-10-09 2010-04-15 Duke University Vhh antibody fragments for use in the detection and treatment of cancer
CA2739352C (en) 2008-10-29 2021-07-13 Wyeth Llc Methods for purification of single domain antigen binding molecules
WO2010108937A2 (en) * 2009-03-27 2010-09-30 Glaxo Group Limited Drug fusions and conjugates
EP2507262A1 (en) 2009-11-30 2012-10-10 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
AR079645A1 (en) 2009-12-18 2012-02-08 Sanofi Aventis ANTAGONIST ANTIBODIES AND THEIR FABRATIONS FAB AGAINST THE PROTEIN OF HUMAN PLATQUETTE MEMBRANES GLICOPROTEIN VI (GPVI) AND ITS USES
TW201144437A (en) 2010-03-03 2011-12-16 Boehringer Ingelheim Int A-beta binding polypeptides
JP6055312B2 (en) 2010-03-10 2017-01-11 ゲンマブ エー／エス Monoclonal antibody against C-MET
WO2012042026A1 (en) * 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
CA3142288A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2723771B1 (en) * 2011-06-23 2019-09-11 Ablynx NV Serum albumin binding proteins
US20150344568A1 (en) 2011-06-23 2015-12-03 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
KR102162413B1 (en) 2011-08-17 2020-10-07 글락소 그룹 리미티드 Modified proteins and peptides
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met

Also Published As

Publication number Publication date
CA2839779C (en) 2020-10-06
AU2012271974A1 (en) 2013-12-12
AU2012271974B2 (en) 2017-01-12
EP2723771A1 (en) 2014-04-30
JP2018127478A (en) 2018-08-16
US20170210789A1 (en) 2017-07-27
PL2723771T3 (en) 2020-04-30
HRP20170535T4 (en) 2022-08-19
SI2723771T1 (en) 2019-12-31
JP2014520129A (en) 2014-08-21
LT2723771T (en) 2019-12-10
WO2012175400A1 (en) 2012-12-27
CN103619878A (en) 2014-03-05
HRP20170535T1 (en) 2017-06-16
HRP20192160T1 (en) 2020-02-21
US9573992B2 (en) 2017-02-21
CN103619878B (en) 2016-10-26
JP7304375B2 (en) 2023-07-06
PT2723771T (en) 2019-12-11
JP6324887B2 (en) 2018-05-16
ES2759936T3 (en) 2020-05-12
HUE047238T2 (en) 2020-04-28
CY1122691T1 (en) 2021-03-12
DK2723771T3 (en) 2019-12-02
JP2021088585A (en) 2021-06-10
EP3466972A1 (en) 2019-04-10
CN106046168A (en) 2016-10-26
US20140228546A1 (en) 2014-08-14
EP4218933A1 (en) 2023-08-02
EP2723771B1 (en) 2019-09-11
JP6843090B2 (en) 2021-03-17
CA2839779A1 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
IN2014CN00414A (en)
WO2008028977A3 (en) Serum albumin binding proteins with long half-lives
PH12019500596A1 (en) Recombinant binding proteins and their use
IN2014CN00437A (en)
MX2013012844A (en) Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same.
MY162737A (en) 4-1bb binding molecules
CA2818990C (en) Designed repeat proteins binding to serum albumin
WO2013040093A3 (en) Glucagon-like peptide-2 compositions and methods of making and using same
AU2016240220B2 (en) Designed ankyrin repeat domains with binding specificity for serum albumin
MX350962B (en) Method for making antibody fc-heterodimeric molecules using electrostatic steering effects.
MX2015008446A (en) Multivalent binding protein compositions.
WO2013184938A3 (en) Fusion polypeptides comprising mucin-domain polypeptide linkers
BR112014032316A2 (en) engineered ankyrin repeat proteins that bind to platelet-derived growth factor
WO2008043822A3 (en) Amino acid sequences that bind to a desired molecule in a conditional manner
DK1888641T3 (en) Serum albumin binding proteins
MX2014011459A (en) Charged nutritive proteins and methods.
EP2250278A4 (en) Methods and compositions related to peptides and proteins with c-terminal elements cross-reference to related applications
WO2009147248A3 (en) Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
IN2014DN05756A (en)
MX2009004243A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use.
MX2015000754A (en) Human btnl3 proteins, nucleic acids, and antibodies and uses thereof.
PH12014501200A1 (en) Bacteriophage gene 3 protein compositions and use as amyloid binding agents
WO2012091564A3 (en) A cross linking polypeptide comprising an hexameric single chain antibody binding mhc-mage complex that induces apoptosis
WO2019014360A8 (en) Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
WO2009138494A3 (en) Amino acid sequences directed against toll-like receptors and their use for the treatment of diseases related to toll-like receptors